9 reports

Similarly, the universities portfolio in Preclinical and Discovery stages comprises ## and ## molecules, respectively.

  • Dementia
  • Stroke
  • Therapy
  • United States
  • Product Initiative

The molecules developed by Companies in Pre-Registration, Filing rejected/ Withdrawn, Phase III, Phase II, Phase I, IND/ CTA Filed, Preclinical, Discovery and Unknown stages are ##, ##, ##, ##, ##, ##, ##, ## and ## respectively.

  • Hospital
  • Stroke
  • Urology
  • United States
  • Nymox Pharmaceutical Corporation

It also provides gastrointestinal agents, antirheumatic, narcotics, vitamin B## supplements and vitamin C supplements, anti-spasmodic, and autonomic nervous systems, among others.

  • Hospital
  • Urology
  • United States
  • Product Initiative
  • Nymox Pharmaceutical Corporation

One external remote patient monitoring device consists of one external module or transmitter.

  • Cardiovascular Disease
  • Stroke
  • Urology
  • United States
  • Pfizer Inc.

Kidney Transplant Rejection - Overview Kidney Transplant Rejection - Therapeutics Development NUMBER OF PRODUCTS UNDER DEVELOPMENT FOR KIDNEY TRANSPLANT REJECTION, H## 2018 PIPELINE OVERVIEW NUMBER OF PRODUCTS UNDER DEVELOPMENT FOR KIDNEY TRANSPLANT REJECTION, H## 2018 Pre-Registration ## ## Ph

  • Monoclonal Antibody
  • Stroke
  • Urology
  • United States
  • Product Initiative
  • STROKE - PIPELINE BY SAVARA INC, H1 2018
  • STROKE - PIPELINE BY SHIN POONG PHARMCO LTD, H1 2018

The company provides cardiovascular, psychoneurotic, anti-cancer, antihistamine, antirheumatic and benign prostatic hyperplasia drugs.

  • Stroke
  • Therapy
  • Urology
  • Company
  • Product Initiative
  • ACUTE ISCHEMIC STROKE - PIPELINE BY SIMCERE PHARMACEUTICAL GROUP, H1 2016

In August 2011, AB Science registered a Phase II/ III multicenter, randomized, double-blind, controlled, ##-parallel groups study to compare efficacy and safety of masitinib at ## and ## mg/ kg/ day to methotrexate, with a randomization ##:##:##, in treatment of pati

  • Research And Development
  • Stroke
  • United States
  • Company Operations
  • AB Science SA
  • ACUTE ISCHEMIC STROKE - PIPELINE BY SIMCERE PHARMACEUTICAL GROUP, H2 2016

In August 2011, AB Science registered a Phase II/ III multicenter, randomized, double-blind, controlled, ##-parallel groups study to compare efficacy and safety of masitinib at ## and ## mg/ kg/ day to methotrexate, with a randomization ##:##:##, in treatment of pati

  • Stroke
  • Therapy
  • Urology
  • Product Initiative
  • AB Science SA